Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes in-depth molecular simulations of both the catalytic and allosteric binding pockets, with ensemble virtual screening focusing on their conformational flexibility. For modulators, the process includes considering the structural shifts due to reaction intermediates to boost activity and selectivity.
Our library stands out due to several important features:
partner
Reaxense
upacc
Q8N4T8
UPID:
CBR4_HUMAN
Alternative names:
3-ketoacyl-[acyl-carrier-protein] reductase beta subunit; Carbonyl reductase family member 4; Quinone reductase CBR4; Short chain dehydrogenase/reductase family 45C member 1
Alternative UPACC:
Q8N4T8; Q8WTW8; Q96K93
Background:
The 3-oxoacyl-[acyl-carrier-protein] reductase, a beta subunit of the KAR heterotetramer complex, plays a pivotal role in mitochondrial fatty acid biosynthesis. It reduces 3-oxoacyl-[ACP] to (3R)-hydroxyacyl-[ACP] in a NADPH-dependent manner, showcasing no preference for chain length. This enzyme, also known as Quinone reductase CBR4, exhibits versatility by reducing various quinones, contributing to cellular protection against cytotoxicity.
Therapeutic significance:
Understanding the role of 3-oxoacyl-[acyl-carrier-protein] reductase could open doors to potential therapeutic strategies.